JMCP

New Data Demonstrates Sempre Health's Solution Leads to Improved Medication Adherence, Lower Emergency Room Visits

Retrieved on: 
Tuesday, January 30, 2024
Conditional sentence, Patient, MD, Pharmacy, Health, SAN, Partnership, Medicine, Stroke, University, Prescription, JMCP, Public, Journal

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- A new peer-reviewed publication in the Journal of Managed Care Pharmacy (JMCP) demonstrates the impact of Sempre Health's innovative behavior-based medication adherence solution in significantly improving patients' consistent use of life-saving medications. Enrolling in Sempre Health's adherence and affordability program led to 18-20% higher medication adherence (dependent on drug class) compared with those not in the program, a meaningful step forward in addressing consistent medication usage challenges associated with chronic diseases.

Key Points: 
  • Sempre Health's program incorporates behavior-based incentives, timely refill reminders, and cost reductions for patients to improve medication affordability and adherence.
  • "The results of this study showing that individuals who used Sempre Health's innovative solution took their medications more often and required fewer ED visits are extremely encouraging.
  • "The statistically significant and higher multi-year medication adherence rates, coupled with a statistically significant reduction in emergency department visits, underscores the impact of Sempre's program.
  • We are not just improving adherence and accessibility of these life-saving drugs; we are positively influencing overall healthcare outcomes," said Anurati Mathur, CEO at Sempre Health.

MC-Rx to Have Abstract Published in Journal of Managed Care & Specialty Pharmacy

Retrieved on: 
Tuesday, October 4, 2022
Nexus, Pharmacist, Pharmacy, Medicare, Government, Academy, Hospice, Physician, JMCP, Author, Poster, PBM, Knowledge, Academy of Managed Care Pharmacy, Multimedia, TPA, Patient safety, Efficiency, Medicaid, Benzodiazepine, AMCP, Nursing, Clinical, Medicine, MD

CAGUAS, Puerto Rico, Oct. 4, 2022 /PRNewswire/ -- Members of the MC-Rx Clinical Staff were informed by the Academy of Managed Care Pharmacy (AMCP) that their Clinical Services Department abstract entitled "Improving patient safety by decreasing co-prescribing of benzodiazepines and opioids" was accepted for a poster presentation at AMCP Nexus 2022 this month. The abstract will be displayed and discussed amongst thousands of attendees from across the nation, the majority of whom are pharmacists, physicians, nurses and other practitioners who manage medication therapies for over 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and the government. Over 300 abstract submissions were received for AMCP Nexus 2022 for possible publication in the Journal of Managed Care & Specialty Pharmacy (JMCP). Each abstract was reviewed and scored via a 2-tier peer-review process: by independent reviewers and then by a JMCP editor. The department's abstract will be published in the JMCP Abstract supplement and authorship of the abstract will be included in the meeting program.

Key Points: 
  • Over 300 abstract submissions were received for AMCP Nexus 2022 for possible publication in theJournal of Managed Care & Specialty Pharmacy(JMCP).
  • Each abstract was reviewed and scored via a 2-tier peer-review process: by independent reviewers and then by a JMCP editor.
  • The department's abstract will be published in the JMCP Abstract supplement and authorship of the abstract will be included in the meeting program.
  • For more information, please contact MC-Rx Clinical Services:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/mc-rx-to-have-abstract-publishe...

scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

Retrieved on: 
Thursday, June 30, 2022
Patient, Research, Cone, Furosemide, JMCP, GLOBE, Ministry of Education (Malaysia), Harvard Pilgrim Health Care, COVID-19, Company, Haemophilia, Heart failure, Medical director, International Arctic Science Committee, Cone Health, Security (finance), Hospital, Medicare Advantage, Education Committee, Clinical peer review, New York Heart Association Functional Classification, LLC, Committee, Solution, Infection, Pharmacy, Medicaid, Committee on Finance, Commercial, AMCP, Biopharmaceutical, NYHA, Private Securities Litigation Reform Act, CV, Board, Coronary artery disease, Congestion, HF, Annual report, Adult, Trial of the century, Vermont Health Connect, U.S. Securities and Exchange Commission, Drug utilization review, Risk, School, Atrial fibrillation, Infertility, Pharmaceutical industry, Medicare, MD

Dr. Bensimhon will discuss the current treatment landscape and unmet medical need in treating adult patients with New York Heart Association (NYHA) Class II and Class III heart failure.

Key Points: 
  • Dr. Bensimhon will discuss the current treatment landscape and unmet medical need in treating adult patients with New York Heart Association (NYHA) Class II and Class III heart failure.
  • Mr. Kenney will provide insights from the payer perspective and discuss the high costs associated with treating heart failure patients.
  • If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
  • The Companys lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease.

CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI

Retrieved on: 
Wednesday, October 20, 2021
Nexus, American Society of Nephrology, Cohort study, ASN, CVC, University Challenge 2013–14, Society, Stroke, Risk, 2021 Essex County Council election, Association, Hospital, Urinary tract infection, Diagnosis, Patient, Incidence, JMCP, Central venous catheter, AMCP, Nasdaq, Gangrene, Female, GLOBE, Pneumonia, ESRD, Industry, Infection, Heart failure, HD, GLM, Medicare, Mortality, Trial of the century, Pharmaceutical industry, Medical device, Health insurance

The AMCP Nexus abstract is published in the JMCP Meeting Abstracts supplement while the ASN abstracts are posted on the conference website.

Key Points: 
  • The AMCP Nexus abstract is published in the JMCP Meeting Abstracts supplement while the ASN abstracts are posted on the conference website.
  • To date, the overall cost burden associated with CRBSI is not fully known.
  • Non-CRBSI control group was identified using an assigned-index date (i.e., CVC insertion date + median days to CRBSI reported in CRBSI-case group).
  • Adjusted generalized linear models (GLM) examined differences in all-cause inpatient hospitalization and total costs between CRBSI and non-CRBSI patients.